key: cord-0775527-wt6bp8os
authors: Tu, Tian Ming; Goh, Claire; Tan, Ying Kiat; Leow, Aloysius ST; Pang, Yu Zhi; Chien, Jaime; Shafi, Humaira; Chan, Bernard PL; Hui, Andrew; Koh, Jasmine; Tan, Benjamin YQ; Umapathi, N. Thirugnanam; Yeo, Leonard LL
title: Cerebral venous thrombosis in patients with COVID-19 infection: a case series and systematic review
date: 2020-10-06
journal: J Stroke Cerebrovasc Dis
DOI: 10.1016/j.jstrokecerebrovasdis.2020.105379
sha: 517e30bf5914010a7d8968bad04d54aaa0bf9999
doc_id: 775527
cord_uid: wt6bp8os

BACKGROUND: : There has been increasing reports associating the coronavirus disease 2019 (COVID-19) with thromboembolic phenomenon including ischemic strokes and venous thromboembolism. Cerebral venous thrombosis (CVT) is a rare neurovascular emergency that has been observed in some COVID-19 patients, yet much remains to be learnt of its underlying pathophysiology. OBJECTIVE: : We present a case series of local patients with concomitant COVID-19 infection and CVT; and aim to perform a systematic review of known cases in the current literature. METHODS: : We describe two patients with concomitant COVID-19 infection and CVT from a nationwide registry in Singapore. We then conducted a literature search in PubMed and Embase using a suitable keyword search strategy from 1st December 2019 to 11th June 2020. All studies reporting CVT in COVID-19 patients were included. RESULTS: : Nine studies and 14 COVID-19 patients with CVT were studied. The median age was 43 years (IQR=36-58) and majority had no significant past medical conditions (60.0%). The time taken from onset of COVID-19 symptoms to CVT diagnosis was a median of 7 days (IQR=6-14). CVT was commonly seen in the transverse (75.0%) and sigmoid sinus (50.0%); 33.3% had involvement of the deep venous sinus system. A significant proportion of patients had raised D-dimer (75.0%) and CRP levels (50.0%). Two patients reported presence of antiphospholipid antibodies. Most patients received anticoagulation (91.7%) while overall mortality rate was 45.5%. CONCLUSIONS: : The high mortality rate of CVT in COVID-19 infection warrants a high index of suspicion from physicians, and early treatment with anticoagulation should be initiated.

Cerebral venous thrombosis (CVT) is a rare neurovascular emergency, and its incidence is estimated to be around 1.6 cases per 100,000 per year in a population-based study [1] . While the occurrence of arterial acute ischemic stroke (AIS) as a devastating neurologic complication is increasingly being reported on, there have been sporadic case reports and case series examining the association between CVT and coronavirus disease 2019 (COVID-19) infection [2] . Several studies have illustrated a higher preponderance to venous thromboembolic manifestations, such as deep vein thrombosis and pulmonary embolism, especially in the critically ill cohorts [3, 4] .

However, the true incidence of cerebral venous thrombosis occurrence in COVID-19 patients remains unknown. Furthermore, the underlying mechanism of CVT in COVID-19 patients remains debatable. It has been proposed that COVID-19 may induce a prothrombotic state, as supported by the elevated levels of factor VIII, fibrinogen, D-dimer and circulating prothrombotic microparticles such as antiphospholipid antibodies [5] [6] [7] .

Given the rapidly rising number of COVID-19 infections globally and the severity of CVT as a complication, it is critical to derive a more in-depth understanding of their association, clinical manifestations, severity and treatment outcomes

In this report, we present a case series of patients with concomitant COVID-19 infection and CVT from Singapore. We subsequently perform a systematic review of the current literature to evaluate patient demographics, clinical characteristics, prothrombotic workup, neuroimaging findings, treatment and outcomes of COVID-19 patients who have suffered CVT.

We identified 3 patients with concomitant COVID-19 infection and CVT from a nationwide registry capturing cases of neurological manifestations in COVID-19 from all public healthcare institutions in Singapore. In 1 patient, CVT was found after significant trauma and was excluded from this case series and analyses. The total number of COVID-19 infections at the time of reporting was obtained from the Ministry of Health, Singapore. Incidence was calculated as the proportion of patients with CVT amongst all COVID-19 cases. We describe the remaining 2 cases and include details on their clinical presentation, prothrombotic workup, neuroimaging findings, treatment and outcomes. Ethics approval was obtained from the Singapore Health Services (CIRB 2020/2410) institutional review board. was resolved by consensus with the senior author (LY). The reference lists of these articles were also screened, and hand searched to identify further relevant studies.

All studies (case reports, case series and observational cohort studies) that reported cerebral venous thrombosis in COVID-19 patients were included during the initial search. We subsequently excluded all studies that reported only acute ischemic stroke, hemorrhagic stroke and those without an English translation.

Relevant quantitative data were extracted by two authors (YKT & CG) in the form of absolute frequencies of events or absolute numbers when appropriate. Where available, the data included incidence rate, individual case data: patient demographics (age, gender), country of study origin, 

The quality of the included case reports and case series was assessed using the guidelines recommended by the Johanna Briggs Institute. For case series, each study was assessed if there were clear inclusion criteria, measured the condition in a reliable way, had a valid method to identify condition, had consecutive or complete inclusion and reported patient demographics, clinical information, and outcomes. For case reports, each study was assessed if the following was well described: patient demographics, medical history, clinical conditions, diagnostic tests, treatment, post-treatment clinical condition, adverse events and takeaway lessons.

All data analysis was conducted using IBM SPSS Statistics 25.0 software. Individual case data were pooled with patient demographics, COVID-19 symptoms, stroke characteristics, treatment and clinical outcomes.

As of 3 July 2020, Singapore had reported 44,479 confirmed COVID-19 cases. Of these COVID-19 cases, we describe 2 patients with concomitant CVT and COVID-19 infection, deriving an incidence of 2/44,479 (0.0045%) or 4.5 per 100,000 COVID-19 cases. 

The electronic search strategy yielded 819 studies, with one additional study found after screening through reference lists. After removing duplicates, 543 records were screened based on abstracts, of which a further 499 studies were excluded as they reported only acute ischemic stroke, hemorrhagic stroke or did not have an English translation. Lastly, 35 articles were excluded after full-text review (reported only on coagulopathy (n=13), venous thromboembolism events unrelated to CVT (n=11), were editorials/opinion letters to editors (n=5), were reviews Presence of CVT in the transverse sinus (75.0%) and sigmoid sinus (50.0%) was seen in the majority of the cases. Involvement of the deep venous sinus system was also commonly observed, with 33.3% having internal cerebral vein or straight sinus thrombosis. Intracranial bleeding was seen on initial neuroimaging in 61.5% of patients.

In terms of laboratory findings, a significant proportion of patients had raised D-dimer (75.0%) and CRP levels (50.0%). Antibody testing was reported in four patients. In the 12 patients with information provided on CVT treatment, most received anticoagulation (91.7%). Of note, Patient 1 underwent percutaneous venous mechanical thrombectomy with adjunct catheter-directed thrombolysis, while Patient 2 had an external ventricular drain inserted due to interval development of venous infarction with hemorrhagic transformation, intraventricular hemorrhage, and obstructive hydrocephalus. Overall, mortality rate reported amongst COVID-19 patients with CVT in this study was 45.5%, while mortality rate amongst the subgroup of mild COVID-19 patients was 40.0%.

This systematic review highlights the occurrence of CVT in patients across the spectrum of severity of COVID-19 infection. Of note, the majority of these patients were middle-aged and without significant comorbidities. The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first recognized in Wuhan after a cluster of atypical pneumonia was reported [17] . Since then, the pandemic has grown rapidly and reached global proportions, overwhelming healthcare systems around the world. Being a novel coronavirus, much is to be learnt about its various clinical manifestations. Interestingly, multiple studies have reported neurological manifestations of the COVID-19 infection, whereby 36.4% of patients were found to have neurological symptoms and that those with severe infection were further associated with strokes and coagulopathy [7, 18] . Indeed, new evidence seems to suggest a tendency for severe COVID-19 infection to trigger cytokine storms which leads to a proinflammatory and prothrombotic state [19] . These patients may thus suffer from thromboembolic events, both arterial and venous [13, 20, 21] . However, it is surprising that in this systematic review of patients with concomitant COVID-19 and CVT, a large majority were relatively young and healthy patients with relatively few co-morbidities. In addition, a significant proportion of CVT patients only displayed mild to moderate severity of COVID-19 infection, thus indicating that a hypercoagulable state may be present even in mild infection.

We propose that the presence of COVID-19 should be screened in patients presenting with neurological complications CVT without prominent respiratory symptoms nor known prothrombotic risk factors. From our systematic review, four (28.6%) patients (case 2, 11, 13 and 14) presented initially with neurological symptoms and all had no prothrombotic risk factors.

Moreover, COVID-19 could have been potentially missed as all 4 had mild respiratory symptoms. For our local 2 cases (13, 14) , COVID-19 was only diagnosed due to pro-active testing with RT-PCR, as they were living in workers dormitories where other cases of COVID-19 were known to occur. Additionally, the incidence of CVT in COVID-19 appears to be approximately 3 times higher than previously published population incidence (4.5 per 100,000 vs 1.6 per 100,000).

The presence of concomitant COVID-19 infection and CVT seems to portend a much poorer prognosis than each condition individually. This study found an unusually high mortality rate of 45.5% in COVID-19 patients diagnosed with CVT, in contrast to the known mortality rates of CVT at 15% and current estimates of COVID-19 case fatality rate of 5.6% [22, 23] . One possibility for the poorer outcome in these patients may be due to the location of the occluded sinuses, which showed a higher predilection for the deep venous sinuses to be involved.

Thrombus in the internal cerebral veins or straight sinus was seen in 33.3% of the patients and these sites of thrombosis are typically rare and have a higher morbidity and mortality rate [24] Consequently, this may be a contributing factor to the high mortality reported in our series, where 50% of the patients who died had involvement of the deep cerebral veins.

Many studies in the current COVID-19 literature have reported cases of arterial and venous thromboembolism, attributed to deranged coagulopathy, extensive systemic inflammation and endothelial dysfunction that are associated with severe COVID-19 [25] . The incidence of venous thromboembolism reported thus far has ranged from 4.4% to 19.7%, with a remarkably high rate seen in the subgroup of severe COVID-19 patients in ICU reaching up to 69% [4, 26, 27] . This has led to several recommendations being made for the use of anticoagulation in hospitalised COVID-19 patients, where those treated with anticoagulation were observed to have improved outcomes [19, 28] . At the same time, anticoagulation with low molecular weight or unfractionated heparin remains the mainstay of treatment in CVT. [29] . Given the higher mortality rates of CVT seen in COVID-19 infection, there may be a role for early initiation of anticoagulation in patients suspected to have CVT or predisposed to its formation. Amongst the patients treated with anticoagulation, 60.0% survived which is an encouraging sign. Lastly, thrombectomy is a therapeutic option in patients with severe CVT, not unlike those with concomitant COVID-19 [24] . In this study, while the only patient (case 1) who underwent endovascular treatment died, this may be related to the need for a salvage endovascular maneuver in a deteriorating patient despite anticoagulation rather than a reflection of the inability of endovascular treatment in COVID-19 patients with CVT.

The following limitations of this study should be acknowledged. Firstly, the patients included in this study were from case reports and case series which are retrospective in nature and may be limited by data availability or accuracy. Secondly, the number of COVID-19 patients with CVT included in the analysis is small (n=14), which did not allow for further comparative analysis.

The actual number of COVID-19 patients with CVT may be significantly higher but not detected as clinical suspicion may be low in a large number of COVID-19 patients who are intubated and without appropriate imaging done. Thirdly, there was insufficient data available from published studies to evaluate the overall incidence of CVT. However, we were able to calculate the local incidence of CVT in COVID-19 patients (4.5 per 100,000), which is higher than the previously published incidence of 1.6 per 100,000 in other population-based studies [1] . Lastly, while the aforementioned factors limit the generalizability of the results, it is nevertheless useful in highlighting a likely association between COVID-19 infection and CVT, serving as a basis for future large cohort studies.

Whilst infrequently reported, CVT has been found to occur in patients with COVID-19 infection.

The unusually high mortality rate warrants a high index of suspicion from physicians, and early treatment with anticoagulation should be initiated in these settings. 

Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study

Characteristics of ischaemic stroke associated with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thrombosis research

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis

Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Cerebral Venous Thrombosis Associated with COVID-19

Cerebral venous thrombosis and SARS-CoV-2 infection

Venous cerebral thrombosis in COVID-19 patient

First case of Covid-19 presented with cerebral venous thrombosis: A rare and dreaded case

Cerebral Venous Sinus Thrombosis as a Presentation of COVID-19

Cerebral Venous Thrombosis: Atypical Presentation of COVID-19 in the Young

Acute Cerebrovascular Disease Following COVID-19: A Single Center

Concomitant brain arterial and venous thrombosis in a COVID-19 patient

Cerebral Venous Thrombosis associated with COVID-19 infection: causality or coincidence

Timeline of who's response to COVID-19

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Thromboinflammation and the hypercoagulability of COVID-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

COVID-19 and ischemic stroke: a systematic review and meta-9 summary of the literature

Real estimates of mortality following COVID-19 infection. The Lancet. Infectious diseases

Cerebral venous thrombosis: an update

Deep cerebral venous thrombosis treatment

COVID-19-Related Stroke

Incidence of venous thromboembolism in hospitalized patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients